ClinicalTrials.gg
CompletedNCT04174170Updated May 30, 2025Results posted

Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder

A Phase 3 interventional study of Brexpiprazole and Sertraline in Post Traumatic Stress Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
591
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sertraline in Stress Disorders, Post-Traumatic — none open to participants now, none under way, none of them phase 3. Sertraline · Stress Disorders, Post-Traumatic.

Enrollment
2nd of 21
591 · median 80
Started
2019
with 2 others
Phase 3
4 of 22
none open now
Registered
21st of 22
by date
Lead sponsor
3 of 22
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 22 studies testing sertraline in Stress Disorders, Post-Traumatic, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2019, is one of 4 in phase 3, and was the 21st registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

None of the 22 studies testing sertraline in Stress Disorders, Post-Traumatic is open now. The open studies under Stress Disorders, Post-Traumatic, anywhere →

Where they have run

About sertraline

Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing sertraline in Stress Disorders, Post-Traumatic as a file.
02

Study summary

This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in adult subjects with post-traumatic stress disorder.

03

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • PTSD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female outpatients 18 to 65 years of age, inclusive, at the time of .
  • Participants who have post-traumatic stress disorder (PTSD), diagnosed according to , 5th edition (DSM-5), and confirmed by the Mini International Neuropsychiatric Interview (MINI).
  • Onset of symptoms meeting the DSM-5 criteria for PTSD symptoms for a minimum of 6 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  • The index traumatic event that led to the development of PTSD took place > 9 years before screening.
  • The index traumatic event occurred before age 16.
  • Participants who have experienced a traumatic event within 3 months of screening.
  • Participants who are receiving disability payments because of PTSD or any other psychiatric disorder; unless the disability payments will not be impacted by potential improvements demonstrated in the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
591 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    All enrolled participants received brexpiprazole-matched placebo tablets and sertraline-matched placebo tablets during the 1-week placebo run-in period.

    Other: Placebo

  • Experimental
    Brexpiprazole (2 mg) + Sertraline

    Randomized participants received brexpiprazole 2 milligrams (mg), orally, once daily (QD) in combination with sertraline, 150 mg, orally, QD from Week 1 to Week 12 of the double-blind treatment (DBT) period.

    Drug: Sertraline · Drug: Brexpiprazole

  • Experimental
    Brexpiprazole (3 mg) + Sertraline

    Randomized participants received brexpiprazole 3 mg, orally, QD in combination with sertraline, 150 mg, orally, QD from Week 1 to Week 12 of the DBT period.

    Drug: Brexpiprazole · Drug: Sertraline

  • Experimental
    Sertraline + Placebo

    Randomized participants received sertraline 150 mg, orally, QD, in combination with sertraline matching placebo, orally, QD from Week 1 to Week 12 of the DBT period.

    Drug: Sertraline · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score

    CAPS-5 was a structured interview designed to assess PTSD diagnostic status and symptoms severity as defined by DSM-5. CAPS -5 total score was calculated by summing severity scores for 20 DSM-5 PTSD symptoms (items 1-20) from categories: Category B: Intrusion symptoms (5 items); Category C: Avoidance symptoms (2 items); Category D: Cognition and mood symptoms (7 items); Category E: Arousal and reactivity symptoms (6 items). CAPS-5 total score was imputed by adding all subscores from categories B, C, D, E. Each symptom was scored 0=Absent to 4=Extreme/incapacitating, to yield a score range of 0-80. Higher scores indicate worse outcome. Least squares (LS) mean was determined by Mixed-effect model repeated measures (MMRM) method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.

    Time frame: Baseline (Week 1), Week 10

Secondary outcomes

  1. Change in Clinical Global Impression - Severity (CGI-S) Score

    The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The score 0 (not assessed) was to be set to missing. The CGI-S is therefore a 7-point scale from 1 through 7. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.

    Time frame: Baseline (Week 1), Week 10

  2. Change in Brief Inventory of Psychosocial Functions (B-IPF) Score

    The B-IPF is a short patient-reported questionnaire consisting of 7 questions which measure PTSD-specific psychosocial function on a 7-point Likert scale (0 = not at all to 6 = very much, and a not applicable option) with a recall period of 30 days. The B-IPF measures the concepts of romantic relationships, parenting, family, friendships and socializing, work, education, and self-care. Total score ranges from 0-100 and is calculated by summing the completed scale items, dividing by the maximum possible score of all items and multiplying by 100. Higher scores indicate greater impairment. LS mean was determined by MMRM method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.

    Time frame: Baseline, Week 12

07

Results

Posted May 30, 2025

Participant flow

A total of 591 participants took part in the study at 75 investigative sites in the United States from 30 October 2019 to 15 August 2023.

Placebo Run-in Period
Participant flow — Placebo Run-in Period
MilestonePlaceboBrexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + Placebo
Started591000
Completed553000
Not completed38000
Withdrew: Not randomized38000
Double Blind Treatment Period
Participant flow — Double Blind Treatment Period
MilestonePlaceboBrexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + Placebo
Started0191185177
Randomized sample0191185177
Enriched randomized sample0143136138
Full analysis set (fas) enriched sample0132126130
Safety sample0185180172
Completed0126123116
Not completed0656261
Withdrew: Adverse event0998
Withdrew: Death0100
Withdrew: Lost to follow-up0221125
Withdrew: Non-compliance with study drug0442
Withdrew: Physician decision0101
Withdrew: Pregnancy0101
Withdrew: Protocol deviation0764
Withdrew: Withdrawal by subject0192914
Withdrew: Reason not specified0136

Outcome measures

PrimaryChange From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score

CAPS-5 was a structured interview designed to assess PTSD diagnostic status and symptoms severity as defined by DSM-5. CAPS -5 total score was calculated by summing severity scores for 20 DSM-5 PTSD symptoms (items 1-20) from categories: Category B: Intrusion symptoms (5 items); Category C: Avoidance symptoms (2 items); Category D: Cognition and mood symptoms (7 items); Category E: Arousal and reactivity symptoms (6 items). CAPS-5 total score was imputed by adding all subscores from categories B, C, D, E. Each symptom was scored 0=Absent to 4=Extreme/incapacitating, to yield a score range of 0-80. Higher scores indicate worse outcome. Least squares (LS) mean was determined by Mixed-effect model repeated measures (MMRM) method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.

Time frame:
Baseline (Week 1), Week 10
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score
score on a scaleBrexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + Placebo
Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score-16.53 ± 1.19-18.28 ± 1.23-17.57 ± 1.19
Statistical analysis
  • Brexpiprazole (2 mg) + Sertraline vs Sertraline + Placebo · MMRM · p = 0.5165 · Treatment difference: 1.03 · 95% CI -2.09 to 4.16
  • Brexpiprazole (3 mg) + Sertraline vs Sertraline + Placebo · MMRM · p = 0.6593 · Treatment difference: -0.71 · 95% CI -3.88 to 2.46
SecondaryChange in Clinical Global Impression - Severity (CGI-S) Score

The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The score 0 (not assessed) was to be set to missing. The CGI-S is therefore a 7-point scale from 1 through 7. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.

Time frame:
Baseline (Week 1), Week 10
Reported as:
Least squares mean · score on a scale
Change in Clinical Global Impression - Severity (CGI-S) Score
score on a scaleBrexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + Placebo
Change in Clinical Global Impression - Severity (CGI-S) Score-1.26 ± 0.10-1.31 ± 0.11-1.29 ± 0.10
Statistical analysis
  • Brexpiprazole (2 mg) + Sertraline vs Sertraline + Placebo · MMRM · p = 0.8215 (MMRM method with model terms: treatment, (pooled) study center, previous pharmacological treatment intervention for PTSD (yes/no), visit, treatment by visit and baseline by visit interaction.) · Treatment difference: 0.03 · 95% CI -0.25 to 0.31
  • Brexpiprazole (3 mg) + Sertraline vs Sertraline + Placebo · MMRM · p = 0.8584 (MMRM method with model terms: treatment, (pooled) study center, previous pharmacological treatment intervention for PTSD (yes/no), visit, treatment by visit and baseline by visit interaction.) · Treatment difference: -0.03 · 95% CI -0.31 to 0.26
SecondaryChange in Brief Inventory of Psychosocial Functions (B-IPF) Score

The B-IPF is a short patient-reported questionnaire consisting of 7 questions which measure PTSD-specific psychosocial function on a 7-point Likert scale (0 = not at all to 6 = very much, and a not applicable option) with a recall period of 30 days. The B-IPF measures the concepts of romantic relationships, parenting, family, friendships and socializing, work, education, and self-care. Total score ranges from 0-100 and is calculated by summing the completed scale items, dividing by the maximum possible score of all items and multiplying by 100. Higher scores indicate greater impairment. LS mean was determined by MMRM method with fixed effect of treatment, trial site, visit week, and an interaction term of treatment by visit week, and included the interaction term of baseline values by visit week as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change in Brief Inventory of Psychosocial Functions (B-IPF) Score
score on a scaleBrexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + Placebo
Change in Brief Inventory of Psychosocial Functions (B-IPF) Score-27.12 ± 2.67-31.79 ± 2.86-22.96 ± 2.71
Statistical analysis
  • Brexpiprazole (2 mg) + Sertraline vs Sertraline + Placebo · MMRM · p = 0.2331 (MMRM method with model terms: treatment, (pooled) study center, previous pharmacological treatment intervention for PTSD (yes/no), visit, treatment by visit and baseline by visit interaction.) · Treatment difference: -4.16 · 95% CI -11.00 to 2.69
  • Brexpiprazole (3 mg) + Sertraline vs Sertraline + Placebo · MMRM · p = 0.0134 (MMRM method with model terms: treatment, (pooled) study center, previous pharmacological treatment intervention for PTSD (yes/no), visit, treatment by visit and baseline by visit interaction.) · Treatment difference: -8.83 · 95% CI -15.82 to -1.85

Adverse events

Collected over From the first dose of the study drug up to 21 days after the last dose (Up to Week 15). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole (2 mg) + Sertraline1/185 (0.5%)1/185 (0.5%)31/185 (16.8%)
Brexpiprazole (3 mg) + Sertraline0/180 (0%)1/180 (0.6%)35/180 (19.4%)
Sertraline + Placebo0/172 (0%)3/172 (1.7%)36/172 (20.9%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + Placebo
ManiaPsychiatric disorders0/1850/1801/172
Suicidal IdeationPsychiatric disorders0/1850/1801/172
HypertensionVascular disorders0/1850/1801/172
Cyst RuptureGeneral disorders0/1851/1800/172
DrowningGeneral disorders1/1850/1800/172
Most frequent other events
Most frequent other events
EventBrexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + Placebo
NauseaGastrointestinal disorders9/18515/18015/172
HeadacheNervous system disorders13/18510/18013/172
DiarrhoeaGastrointestinal disorders7/18511/18011/172
InsomniaPsychiatric disorders7/1857/1809/172

Baseline characteristics

Randomized Sample included all participants randomized into this trial.

Age, Continuous
Age, Continuous(years)Brexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + PlaceboTotal
Mean37.1 ± 12.136.3 ± 11.737.7 ± 12.337.0 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + PlaceboTotal
Female142141126409
Male494451144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + PlaceboTotal
Hispanic or Latino483737122
Not Hispanic or Latino143146140429
Unknown0101
Other0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + PlaceboTotal
White130124121375
Black or African American464544135
American Indian or Alaska Native3126
Asian68519
Native Hawaiian or Other Pacific Islander2103
Other46515
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score(score on a scale)Brexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + PlaceboTotal
Mean38.8 ± 8.337.8 ± 7.339.3 ± 7.838.7 ± 7.8
Clinical Global Impression - Severity (CGI-S) Score
Clinical Global Impression - Severity (CGI-S) Score(score on a scale)Brexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + PlaceboTotal
Mean4.6 ± 0.74.5 ± 0.74.7 ± 0.74.6 ± 0.7
Brief Inventory of Psychosocial Functions (B-IPF) Score
Brief Inventory of Psychosocial Functions (B-IPF) Score(score on a scale)Brexpiprazole (2 mg) + SertralineBrexpiprazole (3 mg) + SertralineSertraline + PlaceboTotal
Mean63.3 ± 20.162.5 ± 22.459.9 ± 20.561.9 ± 21.0
08

Study locations

1 site
  • For additional information regarding sites, contact 844-687-8522
    New York, New York 10010, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jul 2023, 44 months.

Results were first posted in May 2025, 1 year 10 months after primary completion. A results delay was requested in Jul 2024.

Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2019
First posted
Nov 22, 2019
StartActual
Oct 30, 2019
Primary completionActual
Jul 25, 2023
CompletionActual
Aug 15, 2023
Results delay requested
Jul 23, 2024
Results first posted
May 30, 2025
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04174170
Responsible party
Sponsor
First posted
Nov 22, 2019
Start date
Oct 30, 2019
Primary completion
Jul 25, 2023
Completion
Aug 15, 2023
Results posted
May 30, 2025
Last update
May 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brexpiprazole · Sertraline

Start the discussion